The Effects of Vitamin C on Acute-Exercise in Postmenopausal Females

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45+
SponsorUniversity of Virginia

About this trial

This study is looking at whether vitamin C can help improve oxidative stress and blood vessel health in females after menopause. We will see if taking different amounts of vitamin C for a few days changes how the body handles stress from exercise. This could lead to safer ways to protect females from heart disease without using hormone therapy.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Post-menopausal (for females; defined as no menstrual cycle for 1-year)

Sedentary (<150min of moderate-intensity exercise per week or not engaged in a regular exercise program)

Non-smoking

Weight stable (+/-3 kg over the past 3 months)

Disqualifiers

Overt CVD

Any condition or medication contraindicating safe exercise

Hormone replacement therapy (last 3-months)

Use of vasoactive medications (e.g., calcium channel blockers, statins, ACE inhibitors, ARBs, nitrates, alpha-/beta-blockers, diuretics), diabetes, or unstable medication regimens

Trial design

Design model

Crossover

Treatments tested in this trial

  • Vitamin C (Ascorbic Acid)

    Dietary supplement

    Subjects will be supplemented with the following vitamin C doses: 0mg, 200mg, 500mg, 1000mg.

Treatment groups

30 Participants
are divided into 4 treatment groups
Group A: Active Comparator 1: 200mg vitamin CExperimental treatment 1 intervention
Group B: Active Comparator 1: 500mg vitamin CExperimental treatment 1 intervention
Group C: Active Comparator 1: 1000mg vitamin CExperimental treatment 1 intervention
Group D: Placebo Comparator 1: 0mg Vitamin CPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Flow-Mediated Dilation (FMD%) - Brachial Artery Endothelial Function

Brachial artery endothelial function will be measured by flow-mediated dilation (FMD) in each participant 5x (at baseline and after 0mg (placebo) 200mg, 500mg, and 1000mg of vitamin C). Participants will be placed in a supine position with their left forearm slightly extended and supinated with legs straight. The brachial artery will be imaged using a high-resolution 7.5MHz linear array transducer at rest, during 5 minutes of forearm occlusion via cuff inflation (250mmHg), and continuously for 2 minutes post-occlusion; an EKG trigger will be used to capture images during end-diastole of the cardiac cycle.

Time frame
5x: Baseline/un-supplemented; after 3-days of 200mg of vitamin C supplementation; after 3-days of 500mg of vitamin C supplementation; after 3-days of 1000mg of vitamin C supplementation; after 3-days of 0mg of vitamin C/placebo supplementation
2

Basal ROS Concentrations - plasma 8-Isoprostane (8-iso) and malondialdehyde (MDA)

A venous blood sample will be collected from a vein in the antecubital fossa. Plasma will be separated out and stored at -80C until concentrations of 8-Isoprostane (8-iso) and malondialdehyde (MDA) are measured via commerically available ELISA kits. ROS concentrations will be measured at 5x points: at baseline and after 0mg (placebo), 200mg, 500mg, and 1000mg of vitamin C

Time frame
baseline and after 0mg/placebo, 200mg, 500mg, and 1000mg dose of vitamin C for 3-days each
3

Resting ROS/NO Balance - plasma N-oxides (nitrite and nitrate)

Venous blood samples will be collected from an antecubital fossa vein. Plasma will be separated out and stored at -80C until analysis. Plasma N-oxides (nitrite and nitrate) will be evaluated from the plasma via ozone-based chemiluminescence using a Sievers NOA model 280i. The N-oxides will be compared with the basal ROS also measured to calculate a ROS/NO balance.

Time frame
Baseline and after 3-days of placebo, 200mg, 500mg, and 1000mg doses of vitamin C
4

Exercise-Induced ROS (plasma 8-Isoprostane (8-iso) and malondialdehyde (MDA)) and NO (plasma nitrate and nitrite)

An intravenous catheter will be placed into a vein in the antecubital fossa. Participants will complete 4 high-intensity exercise sessions (\~200kcals). Each exercise session will be after 3-days of vitamin C supplementation (0mg/placebo, 200mg, 500mg, and 1000mg). Blood will be collected immediately before, immediately after, 15-min after, and 30-min after exercise. Plasma will be separated out and used to evaluate the changes in ROS (plasma 8-Isoprostane (8-iso) and malondialdehyde (MDA)) and NO (plasma nitrate and nitrite) from baseline/rest.

Time frame
16x points: 4 exercise session with blood will be collected immediately before, immediately after, 15-min after, and 30-min after exercise

Secondary outcomes

1

Vitamin C

Blood samples will be collected to evaluate compliance. We will measure vitamin C concentrations after each supplementation phase.

Time frame
5x points over 5-6 weeks: (1) baseline/unsupplemented and after 3-days of (2) 0mg/placebo, (3) 200mg, (4) 500mg, and (5) 1000mg of vitamin C supplementation
2

Oral Nitrate Reducing Capacity

Assessment of the oral microbiome's ability to reduce nitrate to nitrite. This will be measured through an unstimulated saliva sample and a rinse of a standard nitrate solution.

Time frame
5x points over 5-6 weeks: (1) baseline/unsupplemented and after 3-days of (2) 0mg/placebo, (3) 200mg, (4) 500mg, and (5) 1000mg of vitamin C supplementation
3

Pulse Wave Analysis and Velocity

Brachial artery blood pressures will be obtained using a standard sphygmomanometer. Aortic blood pressures will be obtained using applanation tonometry (SphygmoCor version 8.0, AtCor Medical).

Time frame
5x points over 5-6 weeks: (1) baseline/unsupplemented and after 3-days of (2) 0mg/placebo, (3) 200mg, (4) 500mg, and (5) 1000mg of vitamin C supplementation
4

Microvascular Function

Participants will remain in a supine position with their left or right forearm slight extended and supinated. The cuff used for FMD will remain in place and two circular discs will be placed on the participants extended forearm. A laser Doppler imager (Moor Instruments - FLPI2) will be positioned directly over the participants forearm to measure skin blood flow in three different ways: microvascular flow mediated dilation, acetylcholine, and local thermal heating.

Time frame
5x points over 5-6 weeks: (1) baseline/unsupplemented and after 3-days of (2) 0mg/placebo, (3) 200mg, (4) 500mg, and (5) 1000mg of vitamin C supplementation

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: